Cell Signaling Technology

Product Pathways - Metabolism

Phospho-IRS-1 (Ser1101) Antibody #2385

Applications Reactivity Sensitivity MW (kDa) Source
W IP H M R Endogenous 180 Rabbit

Applications Key:  W=Western Blotting  IP=Immunoprecipitation
Reactivity Key:  H=Human  M=Mouse  R=Rat
Species cross-reactivity is determined by western blot. Species enclosed in parentheses are predicted to react based on 100% sequence homology.

Protocols

Specificity / Sensitivity

Phospho-IRS-1 (Ser1101) Antibody detects endogenous IRS-1 protein only when phosphorylated at serine 1101. The antibody cross-reacts with IRS-2.

Source / Purification

Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Ser1101 of human IRS-1. Antibodies are purified by protein A and peptide affinity chromatography.

Western Blotting

Western Blotting

Western blot analysis of IRS-1 (#2382) antibody-immunoprecipitated pellets from differentiated C2C12 cells, unstimulated, insulin-stimulated (100 nM for 15 min) or PMA-stimulated (200 mM for 30 min), using Phospho-IRS-1 (Ser1101) Antibody (upper) or IRS-1 Antibody #2382 (lower).

IP

IP

Immunprecipitation of Phospho-IRS-1 from insulin treated MCF7 cell extracts using Phospho-IRS-1 (Ser1101) antibody (Lane 1). Lane 2: No antibody control. Lane 3: Input control.

Background

Insulin receptor substrate 1 (IRS-1) is one of the major substrates of the insulin receptor kinase (1). IRS-1 contains multiple tyrosine phosphorylation motifs that serve as docking sites for SH2-domain containing proteins that mediate the metabolic and growth-promoting functions of insulin (2-4). IRS-1 also contains over 30 potential serine/threonine phosphorylation sites. Ser307 of IRS-1 is phosphorylated by JNK (5) and IKK (6) while Ser789 is phosphorylated by SIK-2, a member of the AMPK family (7). The PKC and mTOR pathways mediate phosphorylation of IRS-1 at Ser612 and Ser636/639, respectively (8,9). Phosphorylation of IRS-1 at Ser1101 is mediated by PKCθ and results in an inhibition of insulin signaling in the cell, suggesting a potential mechanism for insulin resistance in some models of obesity (10).

  1. Sun, X.J. et al. (1991) Nature 352, 73-77.
  2. Sun, X.J. et al. (1992) J. Biol. Chem. 267, 22662-22672.
  3. Myers Jr., M.G. et al. (1993) Endocrinology 132, 1421-1430.
  4. Wang, L.M. et al. (1993) Science 261, 1591-1594.
  5. Rui, L. et al. (1997) J. Clin. Invest. 107, 181-189.
  6. Gao, Z. et al. (2002) J. Biol. Chem. 277, 48115-48121.
  7. Horike, N. et al. (2003) J. Biol. Chem. 278, 18440-18447.
  8. Ozes, O.N. et al. (2001) Proc. Natl. Acad. Sci. USA 98, 4640-4645.
  9. De Fea, K. and Ruth, R.A. (1997) Biochemistry 36, 12939-12947.
  10. Li, Y. et al. (2004) J. Biol. Chem. 279, 45304-45307.

Application References

Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!

Companion Products

US Patent No. 7,731,964 and foreign equivalents assigned to Cell Signaling Technology, Inc.

For Research Use Only. Not For Use In Diagnostic Procedures.

Products